ArticleNature communications2021
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 1 pooled it
9.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatment Approaches.Frontiers in oncology · 2021Pooled it
- Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms.Journal of hematology & oncology · 2026Trial
- Trial
- CD69 blockade restores the bone marrow niche and delays leukemogenesis in a mouse model ofCancer biology & therapy · 2026Article
- Functional characterization of the 9q34.13 locus identifies RAPGEF1 as a candidate gene modulating risk for melanoma and nevi via RAS activation.American journal of human genetics · 2026Article
- A structure-based modeling approach identifies effective drug combinations for RAS-mutant acute myeloid leukemia.iScience · 2026Article
- Chronic Myelomonocytic Leukemia: History, Pathobiology, Diagnostic Controversies, and Evolving Classification.Current hematologic malignancy reports · 2026Review
- An Immune Dysfunction Signature Score Predicts Survival in MDS Patients: Insights From a Longitudinal, Multicenter Study.Cancer science · 2026Article
- Recrudescence of a FLT3 wild-type CMML clone after allogeneic stem cell transplant for FLT3-ITD acute myeloid leukemia.The oncologist · 2026Article
- IsolatedHaematologica · 2026Article
- A case of T-prolymphocytic leukemia harboring RAS mutation.Annals of hematology · 2026Article
- Vulnerability of SRSF2-mutated chronic myelomonocytic leukemia to perturbation of the cGAS-STING pathway.Blood advances · 2026Article
- Functional characterization of the 9q34.13 locus identifiesbioRxiv : the preprint server for biology · 2026Article
- Succinate receptor 1 restricts hematopoiesis and prevents acute myeloid leukemia progression.Nature communications · 2026Article
- Article
- A comparative assessment of molecular-based prognostic models in CMML.Blood neoplasia · 2025Article
- Splicing Factor Mutations in Chronic Myelomonocytic Leukemia: Biological Consequences and Therapeutic Implications.Current hematologic malignancy reports · 2025Review
- Toward eRASing the challenge of CMML heterogeneity.Blood advances · 2025Article
- Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia.Blood advances · 2025Article
- Myeloid Neoplasms With Oligomonocytosis Exhibit Heterogenous Pathologic and Genetic Features.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 9 institutions in 4 countries.
Ryan M Carr *Division of Hematology, Department of Internal Medicine, Mayo Clinic, MN, USA.ORCID 0000-0001-5762-367X
Denis Vorobyev *INSERM U981, Gustave Roussy Cancer Center, Villejuif, France.
Terra LashoDivision of Hematology, Department of Internal Medicine, Mayo Clinic, MN, USA.
David L MarksSchulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, MN, USA.
Ezequiel J TolosaSchulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, MN, USA.ORCID 0000-0001-5167-0782
Alexis VedderChemical Biology and Molecular Medicine Program, Moffitt Cancer Center, Tampa, FL, USA.
Luciana L AlmadaSchulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, MN, USA.
Andrey YurchekoINSERM U981, Gustave Roussy Cancer Center, Villejuif, France.
Ismael PadioleauINSERM U981, Gustave Roussy Cancer Center, Villejuif, France.ORCID 0000-0003-4935-3248
Bonnie AlverMolecular Pharmacology and Experimental Therapeutics, Mayo Clinic, MN, USA.
Giacomo ColtroDivision of Hematology, Department of Internal Medicine, Mayo Clinic, MN, USA.
Moritz BinderDivision of Hematology, Department of Internal Medicine, Mayo Clinic, MN, USA.ORCID 0000-0001-9014-9658
Stephanie L SafgrenSchulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, MN, USA.ORCID 0000-0002-5503-7324
Isaac HornSchulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, MN, USA.
Xiaona YouMcArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI, USA.ORCID 0000-0001-9996-1466
Eric SolaryINSERM U1170 and Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France.ORCID 0000-0002-8629-1341
Maria E BalasisChemical Biology and Molecular Medicine Program, Moffitt Cancer Center, Tampa, FL, USA.
Kurt BergerLondon Regional Transgenic and Gene Targeting Facility, Lawson Health Research Institute University of Western Ontario, London, ON, Canada.
James HiebertDivision of Hematology, Department of Internal Medicine, Mayo Clinic, MN, USA.
Thomas WitzigDivision of Hematology, Department of Internal Medicine, Mayo Clinic, MN, USA.ORCID 0000-0002-4215-6500
Ajinkya BuradkarDivision of Hematology, Department of Internal Medicine, Mayo Clinic, MN, USA.
Temeida Graf5TH Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Peter Valent5TH Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Abhishek A MangaonkarDivision of Hematology, Department of Internal Medicine, Mayo Clinic, MN, USA.ORCID 0000-0003-2458-9887
Keith D RobertsonMolecular Pharmacology and Experimental Therapeutics, Mayo Clinic, MN, USA.
Matthew T HowardDepartment of Laboratory Medicine and Pathology, Mayo Clinic, MN, USA.
Scott H KaufmannDivision of Hematology, Department of Internal Medicine, Mayo Clinic, MN, USA.ORCID 0000-0002-4900-7145
Christopher PinLondon Regional Transgenic and Gene Targeting Facility, Lawson Health Research Institute University of Western Ontario, London, ON, Canada.ORCID 0000-0002-1245-1058
Martin E Fernandez-ZapicoSchulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, MN, USA.
Klaus GeisslerSigmund Freud University Vienna, Vienna, Austria.
Nathalie DroinINSERM U1170 and Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France.ORCID 0000-0002-6099-5324
Eric PadronChemical Biology and Molecular Medicine Program, Moffitt Cancer Center, Tampa, FL, USA.
Jing ZhangMcArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI, USA.ORCID 0000-0003-1194-0666
Sergey NikolaevINSERM U981, Gustave Roussy Cancer Center, Villejuif, France. sergey.nikolaev@gustaveroussy.fr.ORCID 0000-0001-8587-2307
Mrinal M PatnaikDivision of Hematology, Department of Internal Medicine, Mayo Clinic, MN, USA. patnaik.mrinal@mayo.edu.ORCID 0000-0001-6998-662X
Mayo Clinic in Arizona · USNovel (United States) · USInserm · FRMoffitt Cancer Center · USMedical University of Vienna · ATUniversity of Wisconsin–Madison · USWestern University · CASigmund Freud Privatuniversität Wien · ATWinnMed · US
Funding
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Lila J. Rutten · 1985 to 2026
$151.3MUW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6MMayo Clinic Center for Translational Science ActivitiesKL2TR000136 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$6.6MThe role of TCOF1 in germline predisposition to and in leukemic transformation of chronic myelomonocytic leukemiaR01CA152108 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Jing Zhang · 2011 to 2026
$5.4MDeveloping and credentialing patient-derived xenograft models to advance therapeutic approaches for chronic myelomonocytic leukemiaR37CA234021 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI PADRON, ERIC · 2019 to 2025
$3.4MMechanism of Pancreatic CarcinogenesisR01CA136526 · NCI · MAYO CLINIC ROCHESTER · PI FERNANDEZ-ZAPICO, MARTIN ERNESTO · 2009 to 2019
$3.0MAustrian Science Fund FWF P 30625NCATS NIH HHS KL2 TR000136NCI NIH HHS P30 CA014520NCI NIH HHS P30 CA015083NCI NIH HHS R01 CA136526NCI NIH HHS R01 CA152108NCI NIH HHS R37 CA234021
Abstract
Proliferative chronic myelomonocytic leukemia (pCMML), an aggressive CMML subtype, is associated with dismal outcomes. RAS pathway mutations, mainly NRAS
Indexed as
MutationAnimalsCell Cycle ProteinsExome SequencingGene Expression ProfilingGene Expression Regulation, LeukemicGTP PhosphohydrolasesHistone-Lysine N-MethyltransferaseKaplan-Meier EstimateLeukemia, Myelomonocytic, ChronicMembrane ProteinsMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicMyeloid-Lymphoid Leukemia ProteinCell Cycle ProteinsGTP PhosphohydrolasesHistone-Lysine N-MethyltransferaseKMT2A protein, humanMembrane ProteinsMyeloid-Lymphoid Leukemia ProteinNRAS protein, humanPolo-Like Kinase 1Protein Serine-Threonine KinasesProto-Oncogene Proteins
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.